Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
Key Highlights
- ➤NOVA Phase 2a study of BMB-101 is under way in Prader-Willi syndrome
- ➤BMB-101 Phase 2a study measures hyperphagia, PWS behaviors, safety, and tolerability
- ➤Bright Minds (DRUG) will participate in FPWR symposium and PWS Family Conference October 7-10
- ➤44,500 common shares issued through option exercise will be returned and cancelled
Expert Statements
Ian McDonald, Chief Executive Officer and Co-founder of Bright Minds Biosciences
“There is no therapy today that adequately addresses the full burden of Prader-Willi Syndrome: the relentless hunger and the behavioral and psychiatric challenges that families live with every day.”
Ian McDonald, Chief Executive Officer and Co-founder of Bright Minds Biosciences
“The FPWR community has shaped how we think about this disease, from the outcome measures we use to the way we design our studies.”
Ian McDonald, Chief Executive Officer and Co-founder of Bright Minds Biosciences
“We are proud to support this year's meeting and to spend time with the families and researchers who are driving progress in PWS.”
Ian McDonald, Chief Executive Officer and Co-founder of Bright Minds Biosciences
“Our NOVA study of BMB-101 is under way.”
Ian McDonald, Chief Executive Officer and Co-founder of Bright Minds Biosciences
“We believe selective 5-HT2C agonism has the potential to address the underlying biology of PWS rather than a single symptom.”
NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the PWS Family Conference, October 9-10, at the Marriott Philadelphia Downtown.
The FPWR meeting brings together families, caregivers, clinicians, researchers, and industry to share the latest in PWS research and care. Bright Minds' participation reflects the Company's commitment to developing a therapy that addresses both hyperphagia and the neurobehavioral symptoms of PWS, and to keeping the PWS community closely involved as its clinical program advances.
Get started
Create a free account to read the full story.